3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Peter Rodriguez of Rice University, Kike Oduba of WellnessWits, and Phil Sitter of RepeatMD. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries recently making headlines in Houston across business, software, and digital health.

Peter Rodriguez, dean of Rice University's Jones Graduate School of Business

Peter Rodriguez joins the Houston Innovators Podcast to discuss the school's growth and development as an innovation leader. Photo courtesy Annie Tao/Rice University

Entrepreneurship doesn't require a MBA from Rice University, but Dean Peter Rodriguez wants to make sure that the students who do pass through the halls of the Jesse H. Jones Graduate School of Business are well prepared for creating a successful company.

"We really want to be the deliverer of the software in people's brain of how to launch great companies and to be trumpeting the opportunities here," he says on the Houston Innovators Podcast.

Rodriguez joined the school as dean in 2016, and since then he's doubled MBA enrollment, grown the tenure-track faculty by over 40 percent, launched an online graduate degree, created an undergraduate business major, and more.

"When I came here, I thought Rice had the best strategic foundation of any university for a great business school — and a lot of that is being really closely connected to Houston and bringing in innovation," he says on the show. Read more.

Kike Oduba, founder and CEO of WellnessWits

WellnessWits, founded by Kike Oduba to enhance patient-physician interaction, has integrated AI with the help of IBM. Photo via WellnessWits.com

A Houston startup aimed at transforming healthcare with solutions for chronic disease and its prevention has teamed up with IBM technology.

WellnessWits has embedded IBM watsonx Assistant into its app for both iOS and Android. By making generative AI part of the app, WellnessWits now boasts an AI-based chat functionality.

That cutting-edge aspect of the platform allows patients to get information on chronic disease more quickly than ever, even before meeting with their physician. But it helps with that, too, aiding in scheduling appointments more easily with doctors who specialize in a host of chronic maladies.

“I founded WellnessWits as a platform for shared medical appointments where doctors with large patient loads can see them in groups and offer collective shared medical experiences to people suffering from chronic conditions. The goal is to bridge this divide, leveraging the strength of digital communities to enhance the overall well-being and healthcare experiences of individuals everywhere,” WellnessWits Founder and CEO Dr. Kike Oduba, a physician and informatician, writes in a blog post. Read more.

Phil Sitter, founder and CEO of RepeatMD

Fresh off a win at the Houston Innovation Awards, Phil Sitter's RepeatMD has raised funding. Photo via RepeatMD

Just nine months after its seed round, a Houston startup with a software platform for the aesthetic and wellness industry has secured $40 million in venture capital and $10 million in debt facility.

RepeatMD, a SaaS platform, announced today that it's secured $50 million, which includes a $10 million debt facility from Silicon Valley Bank. The round was co-led by Centana Growth Partners and Full In Partners with participation from PROOF and Mercury Fund, which also contributed to the seed round earlier this year.

The mobile ecommerce platform, launched in October 2021 by Phil Sitter, targets practices within the med spa and aesthetics industry. In the United States, the med spa market is slated to hit $19 billion in 2023, according to the company's press release, while the global aesthetics market is forecasted to reach to nearly $332 billion by 2030.

“Even though the aesthetics and wellness industry has continued to innovate a growing range of life-changing treatments, practices continue to face challenges selling treatments and services that are new and unfamiliar to patients,” Sitter, CEO of RepeatMD, says in the release. “Our goal at RepeatMD is to give these practice owners the technology to elevate their patients’ experience. Our platform serves as a med-commerce engine equipped with the same firepower as large retailers to convert sales inside and outside of practice operating hours.” Read more.

WellnessWits, founded by Kike Oduba to enhance patient-physician interaction, has integrated AI with the help of IBM. Photo via WellnessWits.com

Houston health tech startup taps into IBM tech for AI integration

teaming up

A Houston startup aimed at transforming healthcare with solutions for chronic disease and its prevention has teamed up with IBM technology.

WellnessWits has embedded IBM watsonx Assistant into its app for both iOS and Android. By making generative AI part of the app, WellnessWits now boasts an AI-based chat functionality.

That cutting-edge aspect of the platform allows patients to get information on chronic disease more quickly than ever, even before meeting with their physician. But it helps with that, too, aiding in scheduling appointments more easily with doctors who specialize in a host of chronic maladies.

“I founded WellnessWits as a platform for shared medical appointments where doctors with large patient loads can see them in groups and offer collective shared medical experiences to people suffering from chronic conditions. The goal is to bridge this divide, leveraging the strength of digital communities to enhance the overall well-being and healthcare experiences of individuals everywhere,” WellnessWits Founder and CEO Dr. Kike Oduba, a physician and informatician, writes in a blog post.

Oduba founded the company in 2018. In its early years, she participated in IBM’s First AI Cohort for Underrrepresented Founders Program. She believes that by using watsonx Assistant in her technology arsenal, WellnessWits will be a means to “digitize, standardize and automate care plans for patients dealing with chronic diseases.”

Diabetes management is a cornerstone of the company, but Oduba says that WellnessWits is similarly committed to impacting health issues including cancer, chronic pain, mental health, and obesity.

“By partnering with IBM, and academic leaders in institutions like The University of Texas, we aim to extend our reach and impact,” Oduba says.

In addition to the IBM program, Oduba and WellnessWits was selected for MassChallenge's recent cohort.

MassChallenge Startup Stories: WellnessWits Founder's Journey from Struggles to SuccessIn this inspiring 6-minute testimonial, we take you through the remarkable experience of Dr. Oduba, founder and CEO of ...

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

View All Listings